Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEL: Ramucirumab and Docetaxel in Stage IV NSCLC
NCT01168973Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Primary completion
- Dec 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Dec 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01168973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01168973.